- Home
- FNWD vs PLX Comparison
FNWD vs PLX Comparison
Compare FNWD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNWD | PLX |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.6M | 142.3M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | FNWD | PLX |
|---|---|---|
| Price | $35.96 | $1.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $34.00 | $12.00 |
| AVG Volume (30 Days) | 20.8K | ★ 557.7K |
| Earning Date | 01-27-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | 0.07 |
| Revenue | ★ $66,563,999.00 | $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | $8.03 | $16.65 |
| P/E Ratio | ★ $18.42 | $26.06 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $26.12 | $1.32 |
| 52 Week High | $39.99 | $3.10 |
Technical Indicators
Market Signals| Indicator | FNWD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 34.14 | 47.51 |
| Support Level | $37.45 | $1.74 |
| Resistance Level | $38.72 | $1.83 |
| Average True Range (ATR) | 0.77 | 0.09 |
| MACD | -0.53 | 0.01 |
| Stochastic Oscillator | 0.00 | 44.83 |
Price Performance
Historical ComparisonAbout FNWD Finward Bancorp
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.